Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Allergies show a small but significant link to later cancer risk

5

Jul 2026

Allergies show a small but significant link to later cancer risk

A systematic review and meta-analysis of 28 cohort-based studies found a weak but statistically significant association between allergic diseases and later cancer incidence. The signal was strongest in the Western Pacific region and among people with asthma, but high heterogeneity and limited subgroup evidence mean the findings require caution.

AI model identifies where snoring starts in the airway

5

Jul 2026

AI model identifies where snoring starts in the airway

A new study developed a snore-source classification model that uses STFT spectrograms, pretrained CNN features, and an L2-regularized SVM to identify where snoring originates in the upper airway. Tested on the MPSSC dataset, the approach achieved a 67.1% test-set unweighted average recall, the highest value among the compared methods, but still needs external clinical validation.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.